Global POC market to increase from $12.8 billion in 2008 to $17.8 billion by 2014, says report

According to a new report distributed by Life Science Intelligence (LSI), the global point-of-care (POC) testing market will experience dramatic growth from $12.8 billion in 2008 to $17.8 billion by 2014. The new report, Worldwide Markets and Emerging Technologies for Point-of-Care Testing, provides a global analysis of the patients, procedures, technologies, and companies driving growth and innovation in the POC testing market.

The report segments the market into three primary areas: hospital bedside testing products; home and self-testing products; and physician's office lab products. Each of these areas is further segmented by product and geography with detailed share-by-supplier information. Various factors driving growth are covered, including: the demands of physicians for more efficient approaches to the delivery of care; demands for faster access to diagnostic test results to optimize patient outcomes in emergency and critical care settings; the development of advanced analytical technologies, including high-sensitivity assays suitable for POC use, as well as microfluidics technologies that enable highly sophisticated assays to be performed at the bedside by non-laboratory personnel, with accuracy equivalent to that achieved in the central laboratory; and advanced computer and communications technologies that allow POC testing to be managed as effectively as tests performed in the central lab.

The study was developed using multiple research methodologies and secondary and primary research, including 238 interviews with leading pathologists and laboratory directors; researchers and technical experts; and company presidents, marketing executives, and business development executives. The report contains 308 pages, 130 exhibits, and coverage of over 250 competitors, including: Abaxis, Abbott Laboratories, Accumetrics, Arkray, Axis-Shield, Bayer Diabetes Care, Beckman Coulter, Biosite, Cepheid, Cholestech, Dexcom, Genzyme, Helena Labs, Hemocue, HemoSense, Home Diagnostics, IDEXX Laboratories/OPTI Medical, International Technidyne/Thoratec, Menarini Diagnostics, Nanogen/ELITech Group, OraSure Technologies, Ortho Clinical Diagnostics/LifeScan, Phamatech, QBC Diagnostics/The Drucker Company, Quidel, Radiometer, Response Biomedical, Roche Diagnostics, Siemens Diagnostics, and Trinity Biotech.


Life Science Intelligence


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New research evaluates clinical trials investigating post-acute COVID-19 syndrome treatment